Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | E7766 |
Synonyms | |
Therapy Description |
E7766 is an agonist of STING, which may potentially activate anti-tumor immune response (Cancer Res 2019;79(13 Suppl):Abstract nr 3269). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
E7766 | E-7766|E 7766 | STING1 Agonist 19 | E7766 is an agonist of STING, which may potentially activate anti-tumor immune response (Cancer Res 2019;79(13 Suppl):Abstract nr 3269). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04144140 | Phase I | E7766 | Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | Terminated | USA | GBR | FRA | ESP | 1 |
NCT04109092 | Phase I | E7766 | A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 | Withdrawn | USA | 0 |